---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-035960"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:17:57.123579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cingulate starts final FDA-required study for lead ADHD asset CTx-1301; raises $10M+

## Summary
- Commenced final FDA-required food effect study for CTx-1301 (dexmethylphenidate) for ADHD; data readout expected by end of 2024.
- Raised over $10M in additional capital since mid-August 2024, including 58% from at-the-market facility.
- Received notification from Nasdaq that company is now in compliance with listing requirements.
- Reinstated CEO/COO/CFO base salaries to original levels ($503K, $424K, $350K) after late-2023 reductions.
- Cost containment measures have saved approximately $1.45M cumulatively; headcount remains ~40% below 2023 levels.

## SEC filing metadata
- accession: 0001493152-24-035960
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315224035960/0001493152-24-035960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315224035960/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-035960
- JSON: https://secwatch.observer/filing/0001493152-24-035960.json
- Plain text: https://secwatch.observer/filing/0001493152-24-035960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.